Drug Class: SGLT2 Inhibitor + Extended-Release Biguanide Combination | Form: Extended-Release Oral Tablet | Prescription Status: Prescription Only (Rx) — DRAP Registered
What is Xenglu Met XR 12.5/1000mg Tablet?
Xenglu Met XR 12.5/1000mg combines Empagliflozin 12.5mg and Metformin Hydrochloride XR 1000mg in a single extended-release tablet. The key distinction from the standard Xenglu Met formulation is the extended-release (XR) Metformin component — designed to release Metformin slowly throughout the day rather than all at once. This slower release significantly reduces the nausea and stomach side effects commonly associated with standard Metformin at 1000mg, while delivering the same maximum therapeutic effect. Together both medicines provide comprehensive blood sugar control alongside cardiovascular and kidney-protective benefits in a once or twice daily extended-release format.
What is Xenglu Met XR 12.5/1000mg Used For?
- Type 2 diabetes mellitus — improving blood sugar control when single-agent therapy is insufficient (ذیابیطس)
- Patients with Metformin intolerance — extended-release formulation is significantly better tolerated than standard Metformin for patients with gastrointestinal sensitivity
- Cardiovascular death risk reduction — Empagliflozin component reduces cardiovascular death risk in patients with established heart disease
- Kidney protection — slowing progression of diabetic kidney damage under medical supervision
- Weight management — Empagliflozin-associated urinary glucose excretion contributes to modest weight reduction
How Does Xenglu Met XR 12.5/1000mg Work?
Empagliflozin 12.5mg — SGLT2 Inhibitor: Blocks SGLT2 transporters in the kidney's proximal tubule, preventing glucose reabsorption back into the bloodstream. Excess glucose is excreted through urine daily — lowering blood sugar independently of insulin. The accompanying fluid and sodium loss produces modest reductions in blood pressure and body weight, contributing to the cardiovascular and kidney-protective benefits of this medicine class.
Metformin Hydrochloride XR 1000mg — Extended-Release Biguanide: Delivers the full 1000mg Metformin dose slowly over an extended period through a controlled-release mechanism. This matches the same blood sugar lowering efficacy as immediate-release Metformin — suppressing hepatic glucose production and improving peripheral insulin sensitivity — while the gradual release dramatically reduces peak plasma concentration spikes responsible for gastrointestinal side effects. Once-daily evening dosing is often possible with XR formulations, further improving convenience and adherence.
Combined Effect: Empagliflozin reduces overall glucose load through urinary excretion while extended-release Metformin controls fasting glucose through sustained liver suppression — providing consistent, comprehensive blood sugar management with significantly better tolerability than immediate-release combinations.
Dosage and Administration
⚠️ Take exactly as prescribed alongside a diabetes-appropriate diet and regular exercise. Never stop without medical advice.
| Indication | Usual Adult Dose | Frequency |
|---|---|---|
| Type 2 diabetes combination therapy | 1 tablet (12.5mg/1000mg XR) | Once or twice daily with meals |
- Always take with meals — even extended-release Metformin is better tolerated with food
- Swallow whole with a full glass of water — never crush, chew, or split the extended-release tablet
- Maintain adequate fluid intake throughout the day — Empagliflozin increases fluid loss through urination
- Regular HbA1c, kidney function, and Vitamin B12 monitoring required during treatment
Active Ingredients
| Ingredient | Strength per Tablet |
|---|---|
| Empagliflozin | 12.5mg |
| Metformin Hydrochloride XR | 1000mg |
Who Should NOT Take Xenglu Met XR 12.5/1000mg?
- Type 1 diabetes — not indicated; increases diabetic ketoacidosis risk
- Severe kidney disease (eGFR below 30) — both components are contraindicated
- Severe liver disease or history of lactic acidosis
- Known allergy to Empagliflozin, Metformin, or any SGLT2 inhibitor
- Recurrent urinary tract or genital fungal infections
- Pregnancy or breastfeeding — avoid; consult doctor immediately
Consult your doctor before use if you have: moderate kidney disease, low blood pressure, heart failure, history of recurrent UTIs or genital infections, or are scheduled for surgery or contrast imaging procedures.
Side Effects
Common:
- Nausea or mild stomach discomfort — significantly reduced compared to standard Metformin due to extended-release mechanism
- Genital yeast infections (thrush) — due to increased urinary glucose from Empagliflozin (فنگل انفیکشن)
- Urinary tract infections — increased urinary glucose raises infection risk
- Increased urination — expected effect of urinary glucose excretion
- Diarrhoea — less common than standard Metformin but possible, particularly during initial weeks
Serious — seek medical attention immediately:
- Lactic acidosis — rare but life-threatening; muscle pain, weakness, difficulty breathing, stomach pain, feeling cold (یہ طبی ہنگامی صورتحال ہے)
- Diabetic ketoacidosis (DKA) — nausea, vomiting, abdominal pain, difficulty breathing — can occur even with near-normal blood sugar
- Severe dehydration — dizziness, fainting, markedly reduced urination
- Fournier's gangrene — rare but serious genital area infection requiring emergency care
- Severe allergic reaction — facial swelling, difficulty breathing, widespread rash
Drug Interactions
| Medicine | Interaction |
|---|---|
| Insulin / Sulphonylureas (e.g., Glibenclamide) | Increased hypoglycaemia risk — dose reduction may be needed |
| Iodinated contrast media (X-ray dye) | Metformin must be stopped before and 48 hours after contrast procedures — kidney failure risk |
| Diuretics (e.g., Furosemide) | Combined fluid loss increases dehydration and low blood pressure risk |
| Alcohol (شراب) | Increases lactic acidosis risk from Metformin — avoid excessive alcohol |
| Corticosteroids | Raise blood sugar and reduce effectiveness of diabetes medicines |
| Antihypertensives | Additive blood pressure lowering — monitor for hypotension |
Storage Instructions
- Store below 30°C away from moisture and direct sunlight
- Swallow whole — never crush or split the extended-release tablet
- Keep out of reach of children (بچوں کی پہنچ سے دور رکھیں)
- Do not use after expiry date on the pack
Frequently Asked Questions (FAQs)
Q: What is the difference between Xenglu Met and Xenglu Met XR? The XR version uses extended-release Metformin that releases slowly throughout the day — providing the same blood sugar control as standard Metformin but with significantly fewer stomach side effects, making it better tolerated at the 1000mg dose.
Q: Why must the XR tablet never be crushed or chewed? Crushing or chewing destroys the extended-release mechanism — releasing the entire 1000mg Metformin dose immediately, which dramatically increases the risk of severe nausea, stomach upset, and side effects.
Q: Can Xenglu Met XR cause low blood sugar on its own? No — neither Empagliflozin nor Metformin causes hypoglycaemia independently. The risk increases only when this combination is used alongside insulin or sulphonylurea medicines.
Q: Should I stop Xenglu Met XR before surgery or a contrast scan? Yes — stop at least 3 days before planned surgery and before any contrast imaging procedure. Restart only after kidney function is confirmed normal and your doctor advises it is safe.
⚕️ Medical Disclaimer: This description is for general information only and does not replace professional medical advice. Always consult your doctor or pharmacist before starting or changing this medicine. Report signs of lactic acidosis or diabetic ketoacidosis immediately — these are medical emergencies.
DRAP Registered | Prescription Required (Rx) | Swallow whole — never crush XR tablet — take with meals — stop before surgery or contrast procedures